Literature DB >> 31076738

HDAC inhibitors tested in phase III trial.

Diana Romero1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31076738     DOI： 10.1038/s41571-019-0224-2

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Zefei Jiang; Wei Li; Xichun Hu; Qingyuan Zhang; Tao Sun; Shude Cui; Shusen Wang; Quchang Ouyang; Yongmei Yin; Cuizhi Geng; Zhongsheng Tong; Ying Cheng; Yueyin Pan; Yuping Sun; Hong Wang; Tao Ouyang; Kangsheng Gu; Jifeng Feng; Xiaojia Wang; Shubin Wang; Tianshu Liu; Jinghua Gao; Massimo Cristofanilli; Zhiqiang Ning; Xianping Lu
Journal:  Lancet Oncol       Date:  2019-04-27       Impact factor: 41.316
  1 in total
  14 in total

Review 1.  Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy.

Authors:  Tianshu Yang; Yunkai Yang; Yan Wang
Journal:  Clin Epigenetics       Date:  2021-05-17       Impact factor: 6.551

Review 2.  Using Chemical Epigenetics to Target Cancer.

Authors:  Virangika K Wimalasena; Tingjian Wang; Logan H Sigua; Adam D Durbin; Jun Qi
Journal:  Mol Cell       Date:  2020-05-13       Impact factor: 17.970

Review 3.  Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.

Authors:  Mengjiao Zhou; Minjian Yuan; Meng Zhang; Chenyi Lei; Omer Aras; Xiaohong Zhang; Feifei An
Journal:  Eur J Med Chem       Date:  2021-09-04       Impact factor: 7.088

Review 4.  Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.

Authors:  Adithya Balasubramanian; Thomas John; Marie-Liesse Asselin-Labat
Journal:  Biochem Soc Trans       Date:  2022-04-29       Impact factor: 4.919

5.  A conserved acetylation switch enables pharmacological control of tubby-like protein stability.

Authors:  Evan M Kerek; Kevin H Yoon; Shu Y Luo; Jerry Chen; Robert Valencia; Olivier Julien; Andrew J Waskiewicz; Basil P Hubbard
Journal:  J Biol Chem       Date:  2020-11-23       Impact factor: 5.157

6.  CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer.

Authors:  Xin-le Han; Jun Du; Ya-Dan Zheng; Jia-Jing Dai; Su-Wen Lin; Bing-Yue Zhang; Fu-Bo Zhong; Zhe-Guang Lin; Shu-Qi Jiang; Wei Wei; Zheng-Yu Fang
Journal:  Biomed Res Int       Date:  2021-04-17       Impact factor: 3.411

7.  Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation.

Authors:  Fuchun Yang; Shaogang Sun; Chenran Wang; Michael Haas; Syn Yeo; Jun-Lin Guan
Journal:  Br J Cancer       Date:  2020-04-27       Impact factor: 7.640

Review 8.  Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas.

Authors:  Yonggang Pei; Josiah H Y Wong; Erle S Robertson
Journal:  Cancers (Basel)       Date:  2020-09-09       Impact factor: 6.639

9.  A Histone Acetylation Modulator Gene Signature for Classification and Prognosis of Breast Cancer.

Authors:  Mengping Long; Wei Hou; Yiqiang Liu; Taobo Hu
Journal:  Curr Oncol       Date:  2021-02-17       Impact factor: 3.677

10.  HDAC inhibition ameliorates cone survival in retinitis pigmentosa mice.

Authors:  Marijana Samardzija; Andrea Corna; Raquel Gomez-Sintes; Mohamed Ali Jarboui; Angela Armento; Jerome E Roger; Eleni Petridou; Wadood Haq; Francois Paquet-Durand; Eberhart Zrenner; Pedro de la Villa; Günther Zeck; Christian Grimm; Patricia Boya; Marius Ueffing; Dragana Trifunović
Journal:  Cell Death Differ       Date:  2020-11-06       Impact factor: 15.828
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.